The Biosimilars Council is calling for inclusion of an affirmative statement to allow for a better understanding of treatment options and more affordable medicines.
Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea in adults.